Advanced Healthcare Materials · 2019 · 29 citations · 38 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryNanoparticle Drug DeliveryTheranosticsCancer Drug DeliveryCancer NanomedicineDrug Delivery BiomaterialsLiposomal FormulationsNanomedicineTheranostic NanoparticlesDrug Delivery NanocarriersLiposomal NanocarriersLiposomesMultifunctional NanoparticlesSmart Drug Delivery SystemsSmart NanoparticlesTheranostic AgentsTheranostic Delivery Systems
Abstract Monodisperse polyethylene glycols–modified (M‐PEGylated) biomaterials exhibit high structural accuracy, biocompatibility, and fine‐tunable physicochemical properties. To develop “smart” drug delivery systems in a controllable and convenient manner, a peptidic M‐PEG “comb” with fluorinated L ‐lysine side chains and a fluorescent N ‐terminal is conveniently prepared as a 19 F magnetic resonance imaging ( 19 F MRI) and fluorescence dual‐imaging traceable and thermo‐responsive “add‐on” module for liposomal theranostics in cancer therapy. The peptidic M‐PEG “comb” has high biocompatibility, thermo‐responsivity with a sharp lower critical solution temperature, an aggregation‐induced emission fluorescence, and high 19 F MRI sensitivity. As a highly branched amphiphile, it self‐assembles and firmly anchors on the doxorubicin‐loaded liposomal nanoparticles, which M‐PEGylates the liposomes and facilitates the thermo‐responsive drug release and drug tracking with dual‐imaging technologies. In a rodent xenograft model of human liver cancer HepG2 cells, the M‐PEGylated liposomes exhibit long in vivo half time, low toxicity, high tumor accumulation, “hot spot” 19 F MRI, and therapeutic efficacy. With accurately programmable chemical structure, fine‐tunable physicochemical and biological properties to meet the demands of diagnosis, drug delivery, and therapy, the M‐PEG “comb” is promising as a versatile “add‐on” module for rapid and convenient formulation of various “smart” theranostics.
38
Qian Chen, Chao Liang, Xiaoqi Sun et al. · Proceedings of the National Academy of Sciences · 2017 · 537 citations · Full text
Pharmacy, Cancer Biology, Oncology +17
Therapeutic antibody fragments with prolonged in vivo half-lives
Andrew P. Chapman, Pari Antoniw, Mariangela Spitali et al. · Nature Biotechnology · 1999 · 348 citations